- Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AML
- Innate Pharma to Participate in Upcoming Investor Conferences
- Innate Pharma to Present IPH6501 Preclinical Data at The EHA 2023 Congress
- Outcome of Innate Pharma’s 2023 Annual General Meeting
- Innate Pharma Reports First Quarter 2023 Financial Results and Business Update
- Number of shares and voting rights of Innate Pharma as of May 1, 2023
- Innate Pharma Announces Conference Call and Webcast for Q1 Business Update
- Innate Pharma Highlights Clinical Abstracts Selected for ASCO 2023 Annual Meeting
- Innate Pharma Establishes a New At-The-Market (“ATM”) Program on Nasdaq
- Innate Pharma to Participate in Upcoming Investor Conference
More ▼
Key statistics
On Friday, Innate Pharma SA (IPH:PAR) closed at 2.78, 39.98% above the 52 week low of 1.99 set on Nov 10, 2022.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.74 |
---|---|
High | 2.84 |
Low | 2.72 |
Bid | 2.72 |
Offer | 2.80 |
Previous close | 2.77 |
Average volume | 53.98k |
---|---|
Shares outstanding | 80.45m |
Free float | 63.03m |
P/E (TTM) | -- |
Market cap | 223.65m EUR |
EPS (TTM) | -0.7292 EUR |
Data delayed at least 15 minutes, as of May 26 2023 16:36 BST.
More ▼